<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[2, 4] wound healing<br>[27, 30] efficacy and tolerability<br>[145, 146] superiority<br>[182, 184] good tolerability<br>[205, 209] Distinct improvement of symptoms<br>[256, 261] enlargement and improvement of effective<br></td>
<td width=33%>
[2, 4] wound healing<br>[27, 30] efficacy and tolerability<br>[145, 146] superiority<br>[182, 184] good tolerability<br>[205, 209] Distinct improvement of symptoms<br>[256, 261] enlargement and improvement of effective<br></td>
<td width=33%>
[2, 4] wound healing<br>[25, 30] examination of efficacy and tolerability<br>[98, 108] assessment of nasal-breathing-resistance according to scores<br>[111, 114] target-parameter<br>[123, 132] Wilcoxon-Mann-Whitney-U two-<br>[145, 150] superiority of the combination of<br>[153, 155] nasal-<br>[165, 175] target-parameter as clinically relevant and statistically significant.<br>[176, 179] clinically proven efficacy<br>[182, 184] good tolerability<br>[198, 200] good compliance<br>[205, 209] Distinct improvement of symptoms<br>[256, 261] enlargement and improvement of effective<br>[262, 265] treatment of rhinitis<br></td>
</tr>
